ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Researchers have developed molecules called synthetic antibody mimics (SyAMs) that target disease-related cells selectively and then recruit immune responses that kill the cells, similar to the functions of natural human antibodies (J. Am. Chem. Soc. 2014, DOI: 10.1021/ja509513c). David A. Spiegel of Yale University, who led the team that developed SyAMs, notes that they are small molecules that can potentially be administered orally, whereas antibodies are proteins that are broken down by the digestive system and must be delivered in other ways. To demonstrate the approach, Spiegel and coworkers designed SyAMs bearing two glutamate-urea groups that recognize prostate-specific membrane antigen, a protein characteristic of prostate cancer cells, and a pair of cyclic peptides that bind to IgG receptor type I, a surface receptor on immune-system macrophages. The SyAMs bind the cancer cells and then recruit macrophages to destroy them. The researchers believe SyAMs may have applications for treating other cancers and viral and bacterial conditions as well. “Currently there are no immediate plans for commercialization, but we have been speaking with several potential partners,” Spiegel says.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X